Other Events ·
Prime Medicine reports $61.2M in cash and short-term investments as of September 30, 2026
PRMEPrime Medicine, Inc.
Prime Medicine announced preliminary unaudited estimates showing approximately $61.2 million in cash, cash equivalents, and short-term investments as of September 30, 2026, excluding restricted cash of $13.7 million. The company has not yet completed its quarter-end financial close process for the period ended September 30, 2026, and these figures are subject to final adjustments. Prime Medicine is a clinical-stage biotechnology company focused on developing gene editing therapies using its proprietary Prime Editing platform.